Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
|Podcasts|February 20, 2023
Pharmacy Focus: Oncology Edition - Pharmacists Play Key Role in Non–Small Cell Lung Cancer
Pharmacists can be involved in all aspects of care, from deciding treatment plans to educating patients, and in the growing role of oral treatments.
Advertisement
This month, we spoke with Jennifer Martin, PharmD, BCOP, a hematology-oncology pharmacist with the Allegheny Health Network. Martin said pharmacists can be involved in all aspects of care, from deciding treatment plans to educating patients, and in the growing role of oral treatments.
Interested in learning more? Check out these related articles:
FDA Approves Adjuvant Pembrolizumab for Non–Small Cell Lung Cancer Medicaid Patients With NSCLC May Be Undertreated With Life-Prolonging Targeted Therapies Expert Discusses PD-1 Inhibitors as Treatment of NSCLC New Digital Tool Provides Resources for Patients With Small Cell Lung Cancer and Their Caregivers
Advertisement
Related to this article
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
A cohort study linked higher BMI and abdominal obesity to increased cancer risk in young adults, reinforcing the importance of early weight management.
Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.
Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
5